Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.

PubWeight™: 0.80‹?›

🔗 View Article (PMID 27647168)

Published in Heart on September 19, 2016

Authors

A John Camm1, Gabriele Accetta2, Giuseppe Ambrosio3, Dan Atar4,5, Jean-Pierre Bassand6, Eivind Berge7, Frank Cools8, David A Fitzmaurice9, Samuel Z Goldhaber10, Shinya Goto11, Sylvia Haas12, Gloria Kayani2, Yukihiro Koretsune13, Lorenzo G Mantovani14, Frank Misselwitz15, Seil Oh16, Alexander G G Turpie17, Freek W A Verheugt18, Ajay K Kakkar2,19, GARFIELD-AF Investigators

Author Affiliations

1: Division of Cardiovascular Sciences, St George's University of London, London, UK.
2: Thrombosis Research Institute, London, UK.
3: Division of Cardiology, University of Perugia School of Medicine, Perugia, Italy.
4: Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway.
5: Faculty of Medicine, University of Oslo, Oslo, Norway.
6: Department of Cardiology, EA 3920, University of Besançon, Besançon, France.
7: Department of Internal Medicine, Oslo University Hospital, Oslo, Norway.
8: AZ Klina, Brasschaat, Belgium.
9: Department of Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK.
10: Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
11: Department of Medicine (Cardiology), Tokai University School of Medicine, Isehara, Japan.
12: Formerly Haemostasis and Thrombosis Research Group, Institute for Experimental Oncology and Therapy Research, Technical University Munich, Munich, Germany.
13: Institute for Clinical Research, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
14: Center for Public Health Research (CESP), University of Milano-Bicocca, Milan, Italy.
15: Bayer HealthCare Pharmaceuticals, Berlin, Germany.
16: Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
17: Department of Medicine, McMaster University, Hamilton, Canada.
18: Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands.
19: Department of Surgery, University College London, London, UK.

Associated clinical trials:

Global Anticoagulant Registry in the Field (GARFIELD-AF) | NCT01090362

Articles cited by this

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis (2002) 81.62

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest (2009) 14.06

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J (2012) 12.36

Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res (2007) 11.09

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med (2010) 4.15

Stroke severity in atrial fibrillation. The Framingham Study. Stroke (1996) 4.11

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation (2014) 3.28

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26

Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol (2012) 2.96

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18

Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J (2008) 2.09

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol (2012) 1.99

Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol (2011) 1.92

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol (2012) 1.76

Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J (2011) 1.75

2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol (2014) 1.70

International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J (2011) 1.20

Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J (2010) 1.07

Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes (2015) 0.88

Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. Stroke (2011) 0.85

National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. Br J Clin Pharmacol (2007) 0.85

A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark. Pharmacoeconomics (2015) 0.79

Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population. Appl Health Econ Health Policy (2015) 0.77

Articles by these authors

Predictors of contemporary coronary artery bypass grafting outcomes. J Thorac Cardiovasc Surg (2014) 1.52

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet (2017) 1.39

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J (2014) 1.25

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol (2016) 1.13

Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes (2015) 0.88

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J (2016) 0.84

Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. Eur Heart J (2017) 0.83

Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. Int J Cardiol (2016) 0.82

The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society. Korean Circ J (2015) 0.82

Regulation and governance of multinational drug trials in stroke: barriers and possibilities. Int J Stroke (2015) 0.79

ABC of antithrombotic therapy: Venous thromboembolism: treatment strategies. BMJ (2002) 0.79

Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation. Am J Cardiol (2013) 0.79

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. Br J Haematol (2016) 0.78

Beneficial Effect of Moderate Exercise in Kidney of Rat after Chronic Consumption of Cola Drinks. PLoS One (2016) 0.77

Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation. JAMA (2014) 0.77

The Theory of Relativity in E (ectopy) and C (coupling): Who Will Prove It? Korean Circ J (2015) 0.75

Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open (2017) 0.75

Prognostic Implication of QRS Variability during Hospitalization in Patients with Acute Decompensated Heart Failure. Korean Circ J (2014) 0.75

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS One (2016) 0.75

Simultaneous Assessment of Systemic and Coronary Endothelial Function: Can We Kill Two Birds With One Stone? Circ Cardiovasc Imaging (2016) 0.75

Patient Characteristics and the Incidence of Radiation-induced Dermatitis Following Radiofrequency Catheter Ablation. Korean Circ J (2016) 0.75

Effects of low-intensity autonomic nerve stimulation on atrial electrophysiology. Korean Circ J (2014) 0.75

Response to letter regarding article, "Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke". Stroke (2014) 0.75

Infections Up to 76 Days After Stroke Increase Disability and Death. Transl Stroke Res (2017) 0.75

Prognostic value of 24-h ABPM in acute ischemic stroke for short-, medium-, and long-term outcome: a systematic review and meta-analysis. Int J Stroke (2015) 0.75

Inverse expression of estrogen receptor alpha and apolipoprotein B in coronary intimal hyperplasia of surgically repaired congenital heart disease: a pre-atherosclerotic condition? Int J Cardiol (2014) 0.75

Assessing the utility of an online registry for patients monitoring their own warfarin therapy. J Clin Pathol (2015) 0.75

The Relationship Between Pericardial Fat and Atrial Fibrillation. J Atr Fibrillation (2013) 0.75

Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. Vascul Pharmacol (2016) 0.75

Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). Int J Stroke (2015) 0.75

Non-valvular atrial fibrillation patients with low CHADS2 scores benefit from warfarin therapy according to propensity score matching subanalysis using the J-RHYTHM Registry. Thromb Res (2015) 0.75

Effects of vitamin K antagonist on aortic valve degeneration in non-valvular atrial fibrillation patients: Prospective 4-year observational study. Thromb Res (2017) 0.75

Risk stratification of Asian patients with heart failure and reduced ejection fraction: the effectiveness of the Echo Heart Failure Score. Eur J Heart Fail (2017) 0.75

Safety of intracoronary provocative testing for the diagnosis of coronary artery spasm. Int J Cardiol (2017) 0.75

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). Eur Heart J Qual Care Clin Outcomes (2017) 0.75

Erratum. Eur Heart J Qual Care Clin Outcomes (2017) 0.75

Evolving quality standards for large-scale registries: the GARFIELD-AF experience. Eur Heart J Qual Care Clin Outcomes (2017) 0.75